Acronym:
CS1002-101
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | All cancers | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase I | Tumour Stream | Solid Tumours |
| Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced |
| Sex | Both | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Solid Tumours |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
A phase I, open-label, multiple dose, dose escalation study of the anti- CTLA-4 monoclonal antibody CS1002 in subjects with advanced solid tumors.
Lay Summary
Sponsor / Cooperative group
Cstone
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Ashford Cancer Centre Research | Helen Daykin | hdaykin@adelaidecancercentre.com.au | 08 8292 2240 | Recruiting |